Published in Am J Physiol on December 01, 1982
Clinical review: Vasopressin and terlipressin in septic shock patients. Crit Care (2004) 1.30
Reductions in central venous pressure by lower body negative pressure or blood loss elicit similar hemodynamic responses. J Appl Physiol (1985) (2014) 1.01
Validation of lower body negative pressure as an experimental model of hemorrhage. J Appl Physiol (1985) (2013) 1.01
Cerebral vasoreactivity during hypercapnia is reset by augmented sympathetic influence. J Appl Physiol (1985) (2010) 0.88
Chronic splanchnic hemodynamic effects of low-dose transdermal nitroglycerin versus low-dose transdermal nitroglycerin plus spironolactone in patients with cirrhosis. Dig Dis Sci (1997) 0.78
Retracted Vasopressin vs Terlipressin in Treatment of Refractory Shock. Transl Med UniSa (2013) 0.77
The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med (1996) 12.77
Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. The SOLVD Investigattors. N Engl J Med (1992) 8.38
Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med (1984) 6.74
Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study. N Engl J Med (1986) 6.58
Lesser response to angiotensin-converting-enzyme inhibitor therapy in black as compared with white patients with left ventricular dysfunction. N Engl J Med (2001) 5.30
Race and the response to adrenergic blockade with carvedilol in patients with chronic heart failure. N Engl J Med (2001) 3.44
Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. US Carvedilol Heart Failure Study Group. Circulation (1996) 3.14
Modern strategies to prevent coronary sequelae and stroke in hypertensive patients differ from the JNC V Consensus Guidelines. Am J Hypertens (1994) 2.91
Evidence of axonal damage in the early stages of multiple sclerosis and its relevance to disability. Arch Neurol (2001) 2.75
Impaired chronotropic response to exercise stress testing as a predictor of mortality. JAMA (1999) 2.74
HAART improves prognosis in HIV-associated progressive multifocal leukoencephalopathy. Neurology (1999) 2.49
Cocaine and chest pain: clinical features and outcome of patients hospitalized to rule out myocardial infarction. Ann Intern Med (1991) 2.45
Right ventricular infarction. Clinical and hemodynamic features. Am J Cardiol (1974) 2.30
Survival in men with severe chronic left ventricular failure due to either coronary heart disease or idiopathic dilated cardiomyopathy. Am J Cardiol (1983) 2.24
Improved left ventricular function during nitroprusside infusion in acute myocardial infarction. Lancet (1972) 2.24
Acute vasoconstrictor response to intravenous furosemide in patients with chronic congestive heart failure. Activation of the neurohumoral axis. Ann Intern Med (1985) 2.22
Validity of the Minnesota Living with Heart Failure questionnaire as a measure of therapeutic response to enalapril or placebo. Am J Cardiol (1993) 2.15
A genomic-systems biology map for cardiovascular function. Science (2001) 2.09
Decreased SLIM1 expression and increased gelsolin expression in failing human hearts measured by high-density oligonucleotide arrays. Circulation (2000) 2.04
Racial differences in response to therapy for heart failure: analysis of the vasodilator-heart failure trials. Vasodilator-Heart Failure Trial Study Group. J Card Fail (1999) 1.96
Role of baroreceptor reflex in daily control of arterial blood pressure and other variables in dogs. Circ Res (1973) 1.95
Axonal metabolic recovery in multiple sclerosis patients treated with interferon beta-1b. J Neurol (2001) 1.91
Activity of the sympathetic nervous system and renin-angiotensin system assessed by plasma hormone levels and their relation to hemodynamic abnormalities in congestive heart failure. Am J Cardiol (1982) 1.91
Acute and long-term response to an oral converting-enzyme inhibitor, captopril, in congestive heart failure. Circulation (1980) 1.88
Age-related abnormalities in arterial compliance identified by pressure pulse contour analysis: aging and arterial compliance. Hypertension (1999) 1.86
Increased plasma arginine vasopressin levels in patients with congestive heart failure. J Am Coll Cardiol (1983) 1.80
Distribution of angiotensin AT1 and AT2 receptor subtypes in the rat kidney. Am J Physiol (1999) 1.79
Treatment of refractory heart failure with infusion of nitroprusside. N Engl J Med (1974) 1.78
Vasodilator therapy for heart failure. The influence of impedance on left ventricular performance. Circulation (1973) 1.78
Role of the renin-angiotensin system in the systemic vasoconstriction of chronic congestive heart failure. Circulation (1978) 1.77
Production and actions of superoxide in the renal medulla. Hypertension (2001) 1.76
New target regions for human hypertension via comparative genomics. Genome Res (2000) 1.75
Vasodilator therapy of cardiac failure: (first of two parts). N Engl J Med (1977) 1.74
Axonal damage correlates with disability in patients with relapsing-remitting multiple sclerosis. Results of a longitudinal magnetic resonance spectroscopy study. Brain (1998) 1.71
Imaging axonal damage of normal-appearing white matter in multiple sclerosis. Brain (1998) 1.68
Systemic and renal hemodynamics in oliguric hepatic failure: effect of volume expansion. J Clin Invest (1967) 1.67
The neurohumoral axis in congestive heart failure. Ann Intern Med (1984) 1.66
Neurohormonal activation in patients with right ventricular failure from pulmonary hypertension: relation to hemodynamic variables and endothelin levels. J Am Coll Cardiol (1995) 1.65
Maximal exercise tolerance as a therapeutic end point in heart failure--are we relying on the right measure? Am J Cardiol (1994) 1.64
Rapid, accurate and simultaneous noninvasive assessment of right and left ventricular mass with nuclear magnetic resonance imaging using the snapshot gradient method. J Am Coll Cardiol (1992) 1.64
Effect of chronic salt loading on adenosine metabolism and receptor expression in renal cortex and medulla in rats. Hypertension (1999) 1.64
Inverse relationship between aldosterone and large artery compliance in chronically treated heart failure patients. Eur Heart J (1998) 1.59
ACE inhibition in cardiovascular disease. N Engl J Med (2000) 1.58
Cardiac troponins and chronic kidney disease. Kidney Int (2006) 1.57
Relationship of exercise capacity to resting left ventricular performance and basal plasma norepinephrine levels in patients with congestive heart failure. Am Heart J (1982) 1.57
Angiotensin II type1a receptor gene expression in the heart: AP-1 and GATA-4 participate in the response to pressure overload. Proc Natl Acad Sci U S A (1997) 1.56
Noninvasive evaluation of cardiac function in hypothyroidism. Response to gradual thyroxine replacement. N Engl J Med (1977) 1.55
HLA-DQA1 and -DQB1 associations with multiple sclerosis in Sardinia and French Canada: evidence for immunogenetically distinct patient groups. Neurology (1993) 1.52
Use of the Living With Heart Failure questionnaire to ascertain patients' perspectives on improvement in quality of life versus risk of drug-induced death. J Card Fail (1995) 1.52
Interferon beta-1b decreases the migration of T lymphocytes in vitro: effects on matrix metalloproteinase-9. Ann Neurol (1996) 1.51
Vasodilator therapy of cardiac failure (second of two parts). N Engl J Med (1977) 1.50
Neurohumoral control mechanisms in congestive heart failure. Am Heart J (1981) 1.47
Prognostic significance of serial changes in left ventricular ejection fraction in patients with congestive heart failure. The V-HeFT VA Cooperative Studies Group. Circulation (1993) 1.42
Plasma norepinephrine, plasma renin activity, and congestive heart failure. Relations to survival and the effects of therapy in V-HeFT II. The V-HeFT VA Cooperative Studies Group. Circulation (1993) 1.41
HTLV-1 associated myelopathy in Canada. Can J Neurol Sci (1989) 1.40
Hydralazine in the long-term treatment of chronic heart failure: lack of difference from placebo. Am Heart J (1982) 1.39
A statistical survey of adverse reactions to LSD in Los Angeles County. Am J Psychiatry (1968) 1.39
The fallacy of the mean. J Card Fail (2001) 1.39
Model-based 3-D segmentation of multiple sclerosis lesions in magnetic resonance brain images. IEEE Trans Med Imaging (1995) 1.39
First- and third-order models for determining arterial compliance. J Hypertens Suppl (1992) 1.38
Nitrate therapy for congestive heart failure. JAMA (1978) 1.37
Contrasting immediate and long-term effects of isosorbide dinitrate on exercise capacity in congestive heart failure. Am J Med (1980) 1.37
Quantification of nitric oxide synthase activity in microdissected segments of the rat kidney. Am J Physiol (1999) 1.36
Systemic alpha-interferon therapy of multiple sclerosis. Neurology (1984) 1.35
Pregnancy outcomes during treatment with interferon beta-1a in patients with multiple sclerosis. Neurology (2005) 1.34
Vascular compliance and cardiovascular disease: a risk factor or a marker? Am J Hypertens (1997) 1.34
Baroreflex modulation of sympathetic outflow during physiological increases of vasopressin in humans. Am J Physiol (1992) 1.29
Sustained hemodynamic effects without tolerance during long-term isosorbide dinitrate treatment of chronic left ventricular failure. Am J Cardiol (1980) 1.29
Regional differences in adrenergic function within the left ventricle. Am J Physiol (1984) 1.28
Effect of isosorbide dinitrate on response to submaximal and maximal exercise in patients with congestive heart failure. Am J Cardiol (1979) 1.27
Role of nitric oxide in renal papillary blood flow and sodium excretion. Hypertension (1992) 1.26
Structural basis for heart failure. Ventricular remodeling and its pharmacological inhibition. Circulation (1995) 1.26
Hemodynamic effects of labetalol, an alpha and beta adrenergic blocking agent, in hypertensive subjects. Circulation (1977) 1.24
Proton magnetic resonance spectroscopic imaging for metabolic characterization of demyelinating plaques. Ann Neurol (1992) 1.24
Interaction of vasopressin and the baroreceptor reflex system in the regulation of arterial blood pressure in the dog. Circ Res (1974) 1.23
Quantitation of portasystemic shunting from the splenic and mesenteric beds in alcoholic liver disease. Am J Med (1972) 1.22
1/f fluctuations in arterial pressure and regulation of renal blood flow in dogs. Am J Physiol (1990) 1.20
Response of plasma norepinephrine and epinephrine to dynamic exercise in patients with congestive heart failure. Am J Cardiol (1982) 1.20
Relationship between C-reactive protein and arterial stiffness in an asymptomatic population. J Hum Hypertens (2005) 1.19